The glow could someday help us use cancer drugs more efficiently.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography (PET) scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
The technique uses PET imaging of a synthesized radiolabeled protein that locks on to tumor cells, letting researchers visually follow where a so-called checkpoint inhibitor drug binds to a tumor as it disperses. “This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person,” says Sridhar Nimmagadda, Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center. If more tests in animals and humans confirm the scan’s precision and safety, its use could streamline cancer therapy by enhancing doctors’ ability to tailor therapy, help determine the therapeutic dose of a drug, and avoid or stop treatments that are not effective, Nimmagadda says.
The study is described in the Feb. 1 issue of The Journal of Clinical Investigation.
Use of checkpoint inhibitors is a type of cancer therapy designed to help the immune system recognize cancer cells as dangerous and target them for destruction. Tumors often hijack these natural protective systems, allowing the tumors to masquerade as healthy tissues. The programmed death ligand 1 (PD-L1) is one such checkpoint target, and it is currently the backbone of immune checkpoint therapies, with three very expensive drugs—atezolizumab, avelumab and durvalumab—now approved by the U.S. Food and Drug Administration (FDA).
However, the Johns Hopkins researchers say, their use is often a shot in the dark, because it’s difficult to predict or quickly track how much PD-L1 is expressed in different tumors and how efficiently those drugs bind to PD-L1 receptors at the tumor in patients.
The research team created a specialized radiolabeled small protein, or peptide, in the lab that binds to PD-L1, which facilitates marking the receptor with a radiotracer that can be seen with PET imaging.
Using their radiolabeled peptide, the researchers investigated whether they could follow the interaction between the drug and the PD-L1 checkpoint protein to measure how thoroughly and quickly the inhibitor drugs bound to this important target in real time.
First, in tests in cells grown in the lab, the researchers confirmed that their radiolabeled peptide would not alter or interfere with the immunotherapy drugs. They said multiple tests showed the radiolabeled peptide bound to PD-L1 with less vigor and could not push off the bound drug. This ability, in theory, would allow the radiolabeled peptide to serve as an efficient marker for PD-L1 proteins still waiting to receive treatment.
They next sought to verify this effect in animals. The researchers treated mice that had implanted human lung tumors with a single dose of atezolizumab—a drug that fights cancer by binding to PD-L1—and waited 24 hours, allowing the checkpoint inhibitor to bind to PD-L1. They followed this treatment with the radiolabeled peptide and PET imaging.
When the mice in the experimental group receiving atezolizumab were compared to controls that received only a saline injection, the researchers found a 77 percent reduction in unoccupied PD-L1 levels in the tumor, indicating that treatment reached many of the PD-L1 proteins.
“The remaining areas indicate parts of the tumor that the immunotherapy didn’t reach,” says Nimmagadda, who is a member of the Institute for Basic Biomedical Sciences at the Johns Hopkins University School of Medicine. “In human patients, this could give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly.”
The researchers then tested whether they could use their method to measure changes in PD-L1 receptor levels on a tumor.
Again using mice with human lung tumors, the researchers treated the rodents with a drug that increases PD-L1 levels in tumor cells. This treatment was followed with the radiolabeled peptide. Upon imaging these mice with PET, they found that the radiotracer levels were 65 percent higher than in control animals with normal levels of PD-L1 receptors. These studies showed that changes in PD-L1 levels could be measured without a biopsy during immune checkpoint therapy.
Additionally, in chemical structure studies of the peptide, the researchers found that peptide binding to PD-L1 is similar to each of the immunotherapy drugs the FDA has approved, suggesting that the same performance observed in their experiments would likely translate to treatments with other immune checkpoint drugs.
“These results represent a necessary initial step toward finding safe, effective and personalized doses of immunotherapy,” says Nimmagadda.
The researchers are working on improving the technique, and they plan to begin clinical trials this year.
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Conflicting data reported on immunotherapy benefit for older NSCLC patients on April 17, 2019 at 10:01 am
medwireNews: The overall survival (OS) benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC) is unclear according to two studies with contradictory results ... […]
- Peanut Oral Immunotherapy Safe for Preschool-Aged Kids in Real-World Setting on April 17, 2019 at 9:59 am
This was the first study to demonstrate the safety of peanut oral immunotherapy among preschool-aged children when administered as routine therapy in a hospital or clinic An analysis published in the ... […]
- Oral immunotherapy for peanut allergy safe for preschoolers on April 17, 2019 at 9:20 am
April 17 (UPI) --It turns out there may be a good treatment for kids who suffer from peanut allergies. About 90 percent of preschool children safely got to the maintenance stage of treatment about 22 ... […]
- Oral immunotherapy safe for preschool-aged children with peanut allergies, study suggests on April 17, 2019 at 8:38 am
New data suggests that oral immunotherapy offered as routine treatment in a hospital or clinic is safe for preschool-aged children with peanut allergies. The research, led by scientists and pediatric ... […]
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Oral immunotherapy safe for preschool-aged children with peanut allergies on April 17, 2019 at 6:45 am
New data published this week in the Journal of Allergy and Clinical Immunology: In Practice suggests that oral immunotherapy is safe for preschool-aged children with peanut allergies. The research ... […]
- Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress on April 17, 2019 at 6:15 am
PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as ... […]
- Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma on April 17, 2019 at 4:19 am
In the version of this article originally published, the graph in Extended Data Fig. 2c was a duplication of Extended Data Fig. 2b. The correct version of Extended Data Fig. 2c is now available online ... […]
- Dr. Socinski on New Applications of Immunotherapy in NSCLC on April 15, 2019 at 1:38 pm
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer (NSCLC). In ... […]
- Figlin Highlights Immunotherapy Developments in RCC on April 15, 2019 at 8:55 am
The emergence of immunotherapy in renal cell carcinoma (RCC) has led to promising approaches to combat the disease, but investigators are still trying to determine how this class of agents compares ... […]
via Bing News